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Short Term Opioid Withdrawal 
Using Buprenorphine 
 
Findings and Strategies from a 
NIDA Clinical Trials Network Study 
 
 
Background Information:  NIDA/SAMHSA Blending Initiative 
The National Institute on Drug Abuse (NIDA) and the Substance Abuse and Mental 
Health Services Administration (SAMHSA) have created a partnership to disseminate 
information to the addiction treatment field. Through the NIDA/SAMHSA Blending 
Initiative, special groups called Blending Teams meet to design dissemination strategies 
and develop research-based products. Members of these Blending Teams come from 
the NIDA-funded National Drug Abuse Treatment Clinical Trials Network (CTN) and the 
SAMHSA-funded Addiction Technology Transfer Center (ATTC) Network. 
 
In the year 1999, NIDA created the National Drug Abuse Treatment Clinical Trials 
Network (CTN). The CTN conducts studies of behavioral, pharmacological, and 
integrated behavioral and pharmacological treatment interventions in rigorous, multi-site 
clinical trials to determine effectiveness across a broad range of community-based 
treatment settings and diverse patient populations. As the CTN research is completed, 
NIDA-funded researchers work with representatives from the ATTC network to provide 
the results and strategies for implementing these findings in clinical settings. This will 
decrease the time it takes for research to be incorporated into treatment settings and will 
thereby improve the quality of drug abuse treatment throughout the country. 
Focus on Buprenorphine 
In 2002, tablet formulations of buprenorphine were approved by the Food and Drug 
Administration (FDA) for the treatment of opiate addiction. Additionally, the CTN 
implemented and completed two clinical trials comparing the use of buprenorphine 
versus clonidine for short-term opioid withdrawal, in both inpatient and outpatient 
settings. The results of these trials suggest that buprenorphine is substantially better 
than clonidine for opioid detoxification.  
   
The results of these trials strongly supported this method of using buprenorphine.  
In order to prepare the field to effectively integrate this treatment method into their 
current practice, NIDA formed a Blending Team to develop a package of training 
materials to instruct providers in how to implement the procedures evaluated through 
these research protocols.  
  
This training assumes some basic information about what buprenorphine is and how it is 
used. One way that this information can be attained is by participating in another training 
developed through the NIDA/SAMHSA Blending Initiative-- Buprenorphine Treatment:  
A Training for Multidisciplinary Addiction Professionals (Buprenorphine 
Awareness). This awareness training is designed for multidisciplinary addiction 
professionals to educate them about buprenorphine and its use in the treatment of opioid 
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addiction. This training was designed to provide a broad overview of the medication, its 
effects, and the role of non-physician practitioners in providing and supporting the 
treatment of individuals receiving this medication.  
 
Blending Team Members  
 Thomas Freese, Ph.D. – Pacific Southwest ATTC – Blending Team Chair  
 Greg Brigham, Ph.D. – CTN Ohio Valley Node  
 Beth Finnerty, M.P.H. – Pacific Southwest ATTC  
 Kay Gresham-Morrison, LCSW, ACSW – Southeast ATTC  
 Judith Harrer, Ph.D. – CTN Ohio Valley Node   
 Dennis McCarty, Ph.D. – CTN Oregon Node  
 Susan Storti, Ph.D., R.N. – ATTC of New England  
 
What Does the Training Package Contain?  
 PowerPoint Training Slides  
 Trainer’s Manual  
 Marketing Brochure  
 
What Does This Trainer’s Manual Contain?  
This training manual, Short Term Opioid Withdrawal Using Buprenorphine, is the 
product of the NIDA/SAMHSA Blending Team. The manual is designed to support a half-
day face-to-face training to review the results from research conducted by the NIDA 
Clinical Trials Network comparing a 13-day detoxification with buprenorphine versus 
clonidine, in both inpatient and outpatient settings. The training will then provide 
instruction for implementing this protocol in treatment settings, including methods of 
evaluation and induction, the taper schedule, and use of ancillary medications during 
treatment.  
 
How Are the PowerPoint Training Slides Organized?  
The training package is designed to provide information and content for a 4-hour 
training. The training should be adapted by adding additional information to meet the 
needs of the audience. . 
 
After providing a background of the Blending Initiative and the medications that will be 
discussed, this course, Short Term Opioid Withdrawal Using Buprenorphine, will 
describe the results of the research on which the training is based. This sets the stage 
for the information that is presented later in the course by providing information about 
why buprenorphine is being used, and the outcomes of this method for tapering people 
off of opioids. The course will then provide an overview of opioid withdrawal and 
symptoms that patients experience during withdrawal. The role of buprenorphine in 
managing withdrawal will then be discussed. Finally, the training will provide a step-by-
step guide for delivering this 13-day taper as it was implemented and evaluated in two 
CTN protocols.  
 
The training is designed as a stand-along module.  Alternatively, it can be incorporated 
into the Buprenorphine Awareness training or adapted in other ways by ATTC and other 
trainers across the country to meet the needs of their local region. Therefore, detailed 
speaker notes, not a word-for-word script, are provided to allow for maximum flexibility. 
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Comments in italics are for the trainer only, and are not meant to be read aloud.  
 
Adaptation of these materials to meet the needs of the specific target audience is 
expected. It is essential that the trainers identify the extent of the attendees’ background 
and experience with opioid treatment, generally, and with using buprenorphine in 
treatment. For instance, if the training audience is a group of physicians who are already 
prescribing buprenorphine, extensive discussion about opioid withdrawal may not be 
warranted. Instead, this section could be replaced with a discussion of the experience of 
inducting the patients onto the medication.  
 
As a rule of thumb, the training should be paced to allow approximately 2 minutes for 
each slide.  
 
General Information about Conducting the Training  
The training can be conducted in any sized group, but small- to medium-sized groups 
(10-25 people) are recommended. Smaller sized groups will ensure adequate time for 
discussion and exploration of questions and concerns with the participants.  
 
Materials Needed to Conduct the Training  
 Computer with PowerPoint software installed (2003 or higher version) and LCD 
projector to project the PowerPoint training slides 
 Flip chart paper and easel/white board, and pens to write down relevant information 
Overall Training Notes  
It is important to find as much out about the training participants as possible prior to the 
training. This will help the trainer(s) to customize the presentation and avoid reviewing 
information that will seem elementary or redundant to the participants.  
 
It is highly recommended that training be conducted or co-conducted with a physician or 
other medical personnel who has experience with buprenorphine treatment. If the trainer 
can pair with one of the physicians who was part of the original CTN studies, this would 
be even better as they would be able to speak directly about their experience with the 
implementation of the protocol described in this training package. At minimum, the 
trainer must have adequate knowledge and experience to be able to discuss some of the 
basic physical symptoms associated with medically-assisted withdrawal from opioids, 
and have a relationship with a physician with whom they can consult if more detailed 
medical questions arise during the training.  
 
Note to speaker      Activity 
 
References 
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Buprenorphine Treatment: 
A Training for Multidisciplinary Addiction Professionals 
 
 
 
Combining the Presentations 
The NIDA/SAMHSA Blending Initiative has developed a suite of products on buprenorphine. 
The Buprenorphine Suite includes the following training curricula: 
 Buprenorphine Treatment: A Training for Multidisciplinary Addiction Professionals 
 Short Term Opioid Withdrawal Using Buprenorphine: Findings and Strategies From a 
NIDA Clinical Trials Network Study 
 Buprenorphine Treatment for Young Adults: Findings and Strategies From a NIDA 
Clinical Trials Network Study 
Each of these curricula is a self-contained training package that can be used to conduct a 
stand-alone training program. However, the Blending Team recognized that in many instances 
trainers may want to incorporate elements of two or all three curricula into a single training 
experience. Combining slides from the presentations may therefore be necessary. Below are 
instructions for combining slides for both PowerPoint 2007 and PowerPoint 1997-2003. 
PowerPoint 2007  
To combine slides into a single presentation, open all presentations from which you will be 
drawing slides. Determine which document will be the master document into which slides from 
the other presentation(s) will be copied. For instance, if you are conducting the Buprenorphine 
Treatment: A Training for Multidisciplinary Addiction Professionals, this would be your master 
document. It is recommended that you save a new copy of this presentation before altering it in 
order to preserve the original training content.
 
I.  Save a new copy of your presentation.  
(1) Click on the program icon in the upper right 
corner of your screen and then (2) click  
on Save As from the drop down menu. Next, (3) 
click on PowerPoint Presentation. A dialogue box 
will appear that will allow you to give the 
presentation a name and location.  
Click in this order: 
1. Program Icon 
2. Save As 
3. PowerPoint Presentation 
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II. Open the presentation from which slides will be copied. 
III. Select Slide Sorter view. 
Go to the Slide Sorter view by (1) clicking on View from the menu at the top of the page and 
then (2) clicking Slide Sorter located on the left side of the page near the top.  
 
 
IV. Select the slides to be copied. 
Slides can be copied in two ways. You can select all slides in the presentation, or you can 
choose only certain slides to copy. Instructions for each are presented below 
Select all slides in presentation. Copy all slides in the presentation by (1) clicking on Home 
from the menu at the top of the page and then (2) clicking on Select on the far right side of the 
page near the top. Next, (3) click on Select All from the drop down menu. All slides in the 
presentation will be highlighted in yellow. 
 
 
 
 
Finally, (4) copy the selected slides to the clipboard by clicking on Copy on the upper left of 
the screen. 
Click in this 
order:  
1. View 
2. Slide Sorter 
Click in this order:  
1. Home     2. Select     3. Select All 
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Select specific slides to copy. To copy only 
certain slides (rather than all of them), on your 
computer keyboard, hold down the control (Ctrl) 
button. While holding down Ctrl, click on the 
slides that you want to copy into the combined 
presentation. Only  slides on which you click will 
be selected (highlighted in yellow). In the close-
up example on the right, Slides 1 and 6 are 
selected (have a yellow box around them). 
Slides 2 and 5 are not selected. 
Once you have clicked on all the slides that you 
want to select, let go of the Ctrl key and then 
click on Copy on the upper left side of the page.   
Note: You may want to practice copying a 
few slides at a time until you are comfortable 
with this procedure. 
 
 
V.  Paste the copied slides into your 
presentation. 
Open your master presentation (the presentation into which the slides are to be copied).  Again 
go to the Slide Sorter view as described in Step III above. (1) Click in the space between the 
slides where you would like the 
copied slides to appear. A flashing 
line will appear between the slides. 
In this example, the copied slides 
will appear after Slide 18. Then (2) 
click on Paste in the upper left 
corner. 
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VI. Maintain original formatting. 
When copying slides from one presentation to the other, the formatting of the copied slides will 
be altered to match the presentation into which they are inserted. However, this often leads to 
significant formatting irregularities. In the example below, Slides 4 to 6 were inserted using the 
method described above. Notice that some of the text is too dark and difficult to read with the 
new formatting. 
 
To prevent this problem, it is recommended that the inserted slides maintain the formatting of 
the original presentation. The following steps show how to do this. 
After pasting the slides into the presentation, you will notice that a small clipboard appears near 
the last inserted slides.   
(1) Click on the clipboard and then (2) click on Keep Source Formatting in the drop-
down menu that appears. 
 
 
 
 
 
 
 
 
 
 
 
This will restore the formatting from the original presentation and ensure that the slides are 
legible when projected during a training session. 
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PowerPoint 1997-2003  
To combine slides into a single presentation, open all presentations from which you will be 
drawing slides. Determine which document will be the master document into which slides from 
the other presentations will be copied. For instance, if you are conducting the Buprenorphine 
Treatment: A Training for Multidisciplinary Addiction Professionals, this would be your master 
document. It is recommended that you save a new copy of this presentation before altering it in 
order to preserve the original training content. 
I.  Save a new copy of your presentation.  
(1) Click on the File button in the upper left corner of the toolbar and then (2) click  
on Save As from the drop-down menu. A dialogue box will appear that will allow you to 
give the presentation a name and location.  
 Click in this order:  
1. File 
2. Save As 
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II. Open the presentation from which slides will be copied. 
 
III. Select Slide Sorter view. 
Go to the Slide Sorter view by (1) clicking on View from the menu at the top of the page and 
then (2) clicking Slide Sorter from the drop-down menu.  
 
 
 
 
IV. Select the slides to be copied. 
Slides can be copied in two ways. You can select all slides in the presentation, or you can 
choose only certain slides to copy. Instructions for each are presented below. 
Click in this 
order:  
1. View 
2. Slide Sorter 
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Select all slides in presentation. Copy all slides in the presentation by (1) clicking on Edit in 
the top toolbar and then (2) clicking Select All from the drop-down menu. All slides in the 
presentation will be highlighted in dark blue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Finally, (3) click on the Edit button in the top toolbar and then click on Copy from the drop-down 
list. 
 
Select specific slides for copying. To copy 
only certain slides (rather than all of them), on 
your computer keyboard, hold down the control 
(Ctrl) button. While holding down Ctrl, click on 
the slides that you want to copy into the 
combined presentation. Only slides on which you 
click will be selected (highlighted in dark blue). In 
the close-up example on the right, Slides 3 and 6 
are selected (have a dark blue border around 
them). Once you have clicked on all the slides 
that you want to select, let go of the Ctrl key and 
then click on the Edit button in the top toolbar 
and then click on Copy from the drop-down 
menu.   
 
Note: You may want to practice copying a few 
slides at a time until you are comfortable with 
this procedure. 
 
V.  Paste the copied slides into your presentation. 
Open your master presentation (the presentation into which the slides are to be copied).  Again 
go to the Slide Sorter View as described in Step III above. (1) Click in the space between the 
slides where you would like the copied slides to appear. A flashing line will appear between the 
Click in this order:  
1. Edit  
2. Select All 
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slides. In this example, the copied slides will appear after Slide 6. Then (2) click on Edit and 
then Paste in the upper left corner. 
 
 
 
 
Click in space where 
slides are to be inserted. 
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VI. Maintain original formatting. 
When copying slides from one presentation to the other, the formatting of the copied slides will 
be altered to match the presentation into which they are inserted. However, this often leads to 
significant formatting irregularities. In the example below, Slides 7 to 9 were inserted into this 
presentation using the method described above. Notice that some of the text is too dark and 
difficult to read with the new formatting. 
 
 
To prevent this problem, it is recommended that the inserted slides maintain the formatting of 
the original presentation. The following steps will show you how to do this. 
After pasting the slides into the presentation, you will notice that a small clipboard appears near 
the last inserted slide.   
(1) Click on the 
clipboard and 
then (2) click on 
Keep Source 
Formatting in 
the drop-down 
menu that 
appears. 
This will restore 
the formatting 
from the original 
presentation 
and ensure that 
the slides are 
legible when 
projected during 
a training 
session. 
 
Three slides 
copied 
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Short Term Opioid Withdrawal Using Buprenorphine  
Slide-By-Slide Trainer Notes  
  
The notes below contain information that can be presented with each slide. This 
information is designed as a guidepost and can be adapted to meet the needs of the 
local training situation. Information can be added or deleted at the discretion of the 
trainer(s).  
 
 
Slide 1:  Short Term Opioid Withdrawal Using 
Buprenorphine  
  
Welcome participants and take care of housekeeping 
details such as location of restrooms, turning off cell 
phones, participate actively, etc.  
  
Briefly describe the development of the Blending 
Team product, as well as the purpose of the training 
as described in the introduction to this manual.  
  
It is important to note that this training is focused on 
educating people about one way of conducting opioid 
detoxification. The training will review some basic 
information about buprenorphine, but participants will 
gain a better understanding of these methods if they 
already have a basic understanding of the medication 
and its mechanism of action.  
 
Reiterate that throughout the training, the term 
“patient” has been used to refer to the individual 
seeking treatment. This terminology reflects the 
medicalized nature of buprenorphine treatment and 
underscores the fact that the treatment is largely 
physician-driven. The use of this term may be 
inconsistent with the vocabulary in common usage in 
the addiction treatment setting. 
 
Also reiterate that throughout the training, the term 
“medication” has been used to refer to buprenorphine 
and buprenorphine/naloxone. This terminology again 
reflects the medicalized nature of buprenorphine 
treatment and underscores the difference between a 
drug of abuse and medication used for the treatment 
of opioid treatment and medically-assisted withdrawal.
 
Slide 1 
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Slide 2:  NIDA/SAMHSA Blending Initiative  
  
Share the definition of “blend” based upon the 
Webster dictionary. 
 
Reference: 
 
blend. (2010). In Merriam-Webster Online Dictionary. Retrieved March 
16, 2010, from http://www.merriam-webster.com/dictionary/blend 
 
Slide 2 
 
Slide 3:  NIDA/SAMHSA Blending Initiative  
  
Developed in 2001 by the National Institute on Drug Abuse 
(NIDA) and the Substance Abuse and Mental Health 
Services Administration’s (SAMHSA) Center for 
Substance Abuse Treatment (CSAT), the NIDA/SAMHSA 
Blending Initiative is designed to meld science and 
practice together to improve substance use disorder 
treatment. The primary goal of this initiative is to develop 
methods for disseminating research findings that will 
accelerate the adoption and implementation of research-
based drug abuse treatment into community-based 
practice.  
 
Blending Products are designed to shorten the time that it 
takes scientific findings to become available in a usable 
way for frontline service providers. This is imperative for 
successful outcomes of clients in addiction treatment 
programs throughout the country. 
 
Slide 3 
 
Slide 4:  Blending Team Members  
 
Blending Teams are composed of NIDA-funded 
researchers, community-based substance abuse 
treatment practitioners and trainers from SAMHSA's 
Addiction Technology Transfer Center (ATTC) Network 
who work closely together to develop the NIDA/SAMHSA 
Blending products.  
 
Note to the Trainer(s):  Acknowledge the members of the 
Blending Team who created this module. Note that the 
membership consisted of four ATTC representatives and 
three NIDA-funded researchers and community treatment 
providers. 
 
Slide 4 
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Slide 5:  Objectives for the Training  
  
There are three primary objectives for this training: 
 To describe opioid withdrawal and the role of 
medical interventions during withdrawal 
 To understand the results of new research on one 
strategy for helping patients withdraw from opioids 
using buprenorphine 
 To define procedures for using buprenorphine to 
conduct a 13-day opioid taper 
 
Slide 5 
 
Slide 6:  Introductions  
 
For smaller groups (20 or less):  Begin the training by 
asking participants to briefly introduce themselves by 
providing their name and the agency for which they 
work, their experience with opioid treatment, and what 
they expect to gain from the training.  
For larger groups:  Personal introductions will take 
too much time to complete. Omit this slide and 
proceed by asking people to identify their role in the 
treatment system by raising their hand.  
At minimum, ask: 
Who is: 
 A direct treatment provider 
 A counselor 
 A nurse 
 A physician 
 A social worker 
 An administrator 
 An educator 
 Anyone that I missed? 
 
Slide 6 
 
 
 
Slide 7:  So who are the participants in this endeavor? 
 
So now we will introduce the key participants who helped 
put these materials together. 
 
Slide 7 
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Slide 8:  An Introduction to SAMHSA/CSAT  
 
The Center for Substance Abuse Treatment (CSAT) of the 
Substance Abuse and Mental Health Services 
Administration (SAMHSA), U.S. Department of Health and 
Human Services (DHHS), was created in October 1992 
with a congressional mandate to expand the availability of 
effective treatment and recovery services for alcohol and 
drug problems. 
 
Slide 8 
 
Slide 9:  SAMHSA/CSAT  
 
Read CSAT mission.  
 
Note to the Trainer(s):  Highlight the importance of the 
research base in all of CSAT’s programming and 
educating the field about the advances of science to 
continually improve the quality of services provided.  
 
Slide 9 
 
Slide 10:  The ATTC Network  
 
One of the major vehicles that SAMHSA has for ensuring 
that the workforce is adequately trained is the Addiction 
Technology Transfer Center (ATTC) Network. 
 
Slide 10 
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Slide 11:  The ATTC Network  
 
Fourteen regional Centers and a National Office constitute 
the ATTC Network, which is dedicated to identifying and 
advancing opportunities for improving addiction treatment.  
  
The vision of the ATTC Network is to unify science, 
education and services to transform the lives of individuals 
and families affected by alcohol and other drug addiction.  
  
Serving the 50 United States, the District of Columbia, 
Puerto Rico, the U.S. Virgin Islands and the Pacific 
Islands, the ATTC Network delivers cutting-edge 
knowledge and skills that develop a powerful workforce. 
 
Slide 11 
 
Slide 12:  An Introduction to the National Institute on 
Drug Abuse  
 
The National Institute on Drug Abuse (NIDA) was 
established in 1974. In October 1992, it became part of the 
National Institutes of Health, Department of Health and 
Human Services.  
  
Recent scientific advances have revolutionized our 
understanding of drug abuse and addiction. The majority 
of these advances, which have dramatic implications for 
how to best prevent and treat addiction, have been 
supported by NIDA. 
 
Slide 12 
 
Slide 13:  The  Mission of NIDA 
 
NIDA is not only seizing upon unprecedented opportunities 
and technologies to further the understanding of how 
drugs of abuse affect the brain and behavior, but also 
working to ensure the rapid and effective transfer of 
scientific data to policy makers, drug abuse practitioners, 
other health care practitioners, and the general public. The 
scientific knowledge that is generated through NIDA-
funded research is a critical element to improving the 
overall health of the Nation. The goal of NIDA is to ensure 
that science, not ideology or anecdote, forms the 
foundation for all of our Nation's drug abuse reduction 
efforts. 
 
Slide 13 
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Slide 14:  So what is this thing called the CTN?  
 
To date, the efficacy of new treatments for drug addiction 
has been demonstrated primarily in specialized research 
settings, with somewhat restricted patient populations. 
This presents a problem when trying to apply these 
findings about new treatments into community-based 
treatment programs, which typically serve diverse 
populations. To address this problem, NIDA established 
the National Drug Abuse Treatment Clinical Trials Network 
(CTN). 
 
Slide 14 
 
Slide 15:  NIDA’s Clinical Trials Network  
 
The mission of the CTN is twofold:  
 Conduct studies of behavioral, pharmacological, and 
integrated behavioral and pharmacological 
interventions to determine therapeutic effect in 
rigorous, multisite clinical trials to determine 
effectiveness across a broad range of community-
based treatment settings and diversified patient 
populations; and  
 Transfer the research results to physicians, providers, 
and their patients to improve the quality of drug abuse 
treatment throughout the country using science as the 
vehicle.  
 
Slide 15 
 
Slide 16:  CTN Node  
 
The CTN is comprised of Nodes that are dispersed across 
the country. Each Node has one Regional Research 
Training Center (RRTC) and 5-10 affiliated community 
treatment programs (CTP). CTN research is conducted in 
the CTPs. CTPs are chosen to participate in a given 
research protocol based on match between the study 
questions and requirements and the populations served by 
the CTP. For instance, in the buprenorphine studies, a 
CTP could be chosen if they served an opioid dependent 
population from whom they could recruit study 
participants.  
 
Slide 16 
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Slide 17:  The Medications:  Buprenorphine and 
Clonidine (Transition Slide) 
  
Before we discuss the specifics of the research conducted, 
we will spend a few minutes talking about the medications 
being investigated and why they were chosen. In the next 
section we will look at the mechanism of action of these 
medications and issues pertaining to their efficacy and 
safety. 
 
Slide 17 
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Slide 18:  Partial vs. Full Opioid Agonist and 
Antagonist 
 
This slide graphically depicts the different types of opioids 
(whether they are prescribed medications, such as Vicodin 
or methadone, or an illicit substance, like heroin). 
Move forward to reveal first line (full agonist) 
Full agonists (e.g., heroin, opium, Vicodin, methadone, 
etc.) fully activate the receptors so that the more you 
use, the more effect you experience. If someone 
continues to use, they will eventually experience 
overdose and, possibly, death.  
The following metaphor may be helpful in explaining 
the differences between the types of opioids: 
Opioid agonists work like having the right key to a door. 
You put the key in the lock, the lock turns and the door 
opens completely.  
Move forward to reveal the next line (antagonists) 
Opioid antagonists (e.g., naltrexone, naloxone) fill the 
receptors and block the action of other opioids. If the 
person has used an opioid agonist, the antagonist will 
replace it on the receptor and the person will experience 
withdrawal. If the person is stable on an antagonist, and 
uses another opioid, the antagonist will block the effects, 
preventing the user from experiencing the high. 
The door metaphor continued: 
Opioid antagonists work like having the wrong key to a 
door. You put the key in the lock; the door remains 
locked and will not open. Additionally, since the key is in 
the lock, no other key can be put in the lock (even if it is 
the right key for that door) until the wrong key is 
removed. 
Move forward to reveal the last line (partial agonists) 
Opioid partial agonists (e.g., buprenorphine) are in the 
middle. At lower doses, they work just like agonists, 
filling the receptor and preventing withdrawal symptoms. 
However, as the dose increases, a ceiling effect occurs 
so that if more is used, no more effect is achieved. This 
ceiling effect applies both to opioid euphoria (they don’t 
feel high), and to the respiratory suppression (making 
overdose less likely). 
The door metaphor continued: 
Opioid partial agonists work like having the right key to a 
door, but the chain is on the door. The key goes in and 
opens the door, but it will only open so far.  
Slide 18 
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Slide 19:  Buprenorphine  
  
As mentioned in the previous slide, buprenorphine is a 
partial agonist. It has been shown to be safe and effective 
for the treatment of opioid dependence both as a 
maintenance agent and for use during withdrawal from 
opioids. 
Buprenorphine binds to the receptors very strongly 
(affinity) and comes off very slowly (dissociation). This 
makes it a very long-lasting medication that continues to 
be effective even if a dose is missed.  
Clinical trials have demonstrated that buprenorphine is a 
safe and effective medication for both opioid maintenance 
and medically-assisted withdrawal (detoxification).  
 
Another advantage is that the FDA approval for the 
medication is for opioid dependent individuals age 16 and 
older. It is possible to use the medication with younger 
adolescents if determined medically appropriate (benefits 
outweigh the risks). However, this would be off-label use 
and the patients must be monitored very closely due to the 
lack of clinical research data. 
 
It may be worth noting that buprenorphine is the only 
medication with FDA approval that is not schedule II 
(whereas, methadone is schedule II), and that only 
Suboxone and Subutex are approved.  
 
Although Buprenex® (injectable formulation of 
buprenorphine) and Talwin® (Pentazocine) are also partial 
opioid agonists and approved for the treatment of pain; 
they ARE NOT approved for the treatment of opioid 
addiction.  
 
Note to the Trainer(s):  It is important to review the 
definition of “affinity”, “intrinsic activity,” and “dissociation” 
(CSAT, 2004) as these terms will be referenced 
throughout the module. 
 Affinity:  The strength with which a drug binds to its 
receptor 
 Intrinsic activity:  the degree to which a drug 
activates its receptors  
 Dissociation:  a measure of the disengagement or 
uncoupling of the drug from the receptor.  
 
Reference: 
Center for Substance Abuse Treatment. Clinical Guidelines for the Use 
of Buprenorphine in the Treatment of Opioid Addiction. Treatment 
Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 
04-3939. Rockville, MD: Substance Abuse and Mental Health Services 
Administration, 2004. 
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Slide 20:  Development of Tablet Formulations of 
Buprenorphine  
 
Buprenorphine was developed by a pharmaceutical 
company called Reckitt Benckiser. They had exclusive 
marketing rights until Fall 2009, and distribute the 
medication as:  
 
Subutex® = a sublingual tablet containing buprenorphine 
hydrochloride only  
  
Suboxone® = a sublingual tablet containing both 
buprenorphine hydrochloride and naloxone hydrochloride 
in a 4:1 ratio  
  
Reckitt Benckiser’s exclusive rights expired in the fall of 
2009, so generic versions of the medication may become 
available in the future.  
 
Buprenorphine/naloxone is the focus of U.S. marketing 
efforts, even though both formulations are available in the 
United States.  
 
These medications have a tremendous amount of 
research behind them to show that they are both safe and 
effective in the treatment of opioid addiction. 
 
Slide 20 
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Slide 21:  Buprenorphine:  A Science-Based Treatment 
 
In the development of the medication, the effectiveness of 
buprenorphine has been compared to that of other 
currently available medications. These studies have 
shown that buprenorphine treatment: 
 is more effective than placebo; and 
 has similar effectiveness to moderate doses of 
methadone and LAAM. 
 
References: 
 
Fischer, G., Gombas, W., Eder, H., Jagsch, R., Peternell, A., 
Stuhlinger, G., et al. (1999). Buprenorphine versus methadone 
maintenance for the treatment of opioid dependence. Addiction, 94(9), 
1337-1347. 
 
Johnson, R. E., Jaffe, J. H., & Fudala, P. J. (1992). A controlled trial of 
buprenorphine treatment for opioid dependence. Journal of the 
American Medical Association, 267, 2750–2755. 
 
Johnson, R. E., Eissenberg, T., Stitzer, M. L., Strain, E. C., Liebson, I. 
A., & Bigelow, G. E. (1995) A placebo controlled clinical trial of 
buprenorphine as a treatment for opioid dependence. Drug and Alcohol 
Dependence, 40(1), 17-25. 
 
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. 
L., & Bigelow, G. E. (2000). A comparison of levomethadyl acetate, 
buprenorphine, and methadone for opioid dependence. New England 
Journal of Medicine, 343(18), 1290-1297. 
Kakko, J., Svanborg, K., Kreek, M., & Heilig, M. (2003). 1-year retention 
and social function after buprenorphine-assisted relapse prevention 
treatment for heroin dependence in Sweden: A randomised, placebo-
controlled trial. The Lancet, 361(9358), 662-668. 
 
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Jr., 
Kintaudi, P., et al. (1998) Buprenorphine maintenance treatment of 
opiate dependence: A multicenter, randomized clinical trial. Addiction, 
93, 475–486. 
 
Schottenfeld, R. S., Pakes, J. R., Oliveto, A., Ziedonis, D., & Kosten T. 
R. (1997). Buprenorphine vs methadone maintenance treatment for 
concurrent opioid dependence and cocaine abuse. Archives of General 
Psychiatry, 54, 713–720. 
 
Strain, E. C., Stitzer, M. L., Liebson, I. A., & Bigelow, G. E. (1994). 
Comparison of buprenorphine and methadone in the treatment of opioid 
dependence. American Journal of Psychiatry, 151, 1025–1030. 
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Slide 22:  Buprenorphine Research Outcomes  
 
Clinical trials have established the effectiveness of 
buprenorphine for the treatment of opioid addiction. The 
clinical studies have shown the following about 
buprenorphine:  
Bullet #1:  Patients on buprenorphine did as well as 
patients on a moderate dose of methadone (e.g., 60 mg).  
Bullet #2:  Patients on buprenorphine did as well as 
patients on a moderate dose of LAAM (70mg/70mg/85mg 
on a Monday/Wednesday/Friday schedule).  
Bullet #3:  Patients found that taking buprenorphine was a 
pleasant experience, which encouraged them to be 
compliant. 
Bullet #4:  When compared to placebo-plus-counseling, 
3/4 of the patients receiving buprenorphine and counseling 
were still in treatment after one year. None of the placebo 
patients were retained.  
 
References: (Bullet #1) 
Fischer, G., Gombas, W., Eder, H., Jagsch, R., Peternell, A., 
Stuhlinger, G., et al. (1999). Buprenorphine versus methadone 
maintenance for the treatment of opioid dependence. Addiction, 94(9), 
1337-1347. 
Johnson, R. E., Jaffe, J. H., & Fudala, P. J. (1992). A controlled trial of 
buprenorphine treatment for opioid dependence. Journal of the 
American Medical Association, 267, 2750–2755. 
Schottenfeld, R. S., Pakes,  J. R., Oliveto, A., Ziedonis, D., & Kosten T. 
R. (1997). Buprenorphine vs methadone maintenance treatment for 
concurrent opioid dependence and cocaine abuse. Archives of General 
Psychiatry, 54, 713–720. 
Strain, E. C., Stitzer, M. L., Liebson, I. A., & Bigelow, G. E. (1994). 
Comparison of buprenorphine and methadone in the treatment of opioid 
dependence. American Journal of Psychiatry, 151, 1025–1030.  
Reference: (Bullet #2) 
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. 
L., & Bigelow, G. E. (2000). A comparison of levomethadyl acetate, 
buprenorphine, and methadone for opioid dependence. New England 
Journal of Medicine, 343(18), 1290-1297. 
Reference: (Bullet #3) 
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Jr., 
Kintaudi, P., et al. (1998) Buprenorphine maintenance treatment of 
opiate dependence: A multicenter, randomized clinical trial. Addiction, 
93, 475–486.  
Reference: (Bullet #4) 
Kakko, J., Svanborg, K., Kreek, M., & Heilig, M. (2003). 1-year retention 
and social function after buprenorphine-assisted relapse prevention 
treatment for heroin dependence in Sweden: A randomised, placebo-
controlled trial. The Lancet, 361(9358), 662-668. 
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Slide 23:  Why did they make two formulations? 
 
As previously stated, the focus of marketing in the United 
States and the formulation used in the CTN studies is the 
buprenorphine/naloxone combination. Understanding why 
this combination was made is critical. 
 
Slide 23 
 
Slide 24:  Advantages of Buprenorphine/Naloxone  
  
The buprenorphine/naloxone formulation has some 
advantages  compared with the buprenorphine only 
formulation: 
 It discourages injection of the product because, when 
injected, the naloxone will lead to withdrawal, 
whereas when taken sublingually as prescribed, it will 
not have that effect.  
 Because of the above point, the combination tablet 
lowers the likelihood that the medication will be 
diverted.  
 
Slide 24 
 
Slide 25:  Use of Buprenorphine:  Studies on Cost-
Effectiveness 
  
There has been much discussion regarding the costs 
associated with the use of buprenorphine for the treatment 
of opioid dependence. When considering the costs of 
providing treatment, you must also include costs 
associated with clinic visits, staff time, and general 
operating and facility expenditures.  
 
Recently, research conducted on adult populations has 
demonstrated the utilization of buprenorphine is cost 
effective across several indicators. 
 
Slide 25 
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Slide 26:  Use of Buprenorphine:  Studies on Cost-
Effectiveness 
  
Doran and colleagues (2003) conducted a clinical trial 
designed to assess the safety, efficacy and cost-
effectiveness of buprenorphine versus methadone in the 
management of opioid dependence. The trial utilized a 
flexible dosing regime that was tailored to the clinical need 
of the patients, with high maximum doses, using the 
marketed tablet formulation, under double-blind conditions. 
A total of 405 subjects were randomized to a treatment at 
one of three specialist outpatient drug treatment centers in 
Adelaide and Sydney, Australia. The perspective of the 
cost-effectiveness analysis was that of the service provider 
and included costs relevant to the provision of treatment. 
The primary outcome measure used in the economic 
analysis was change in heroin-free days from baseline to 
the sixth month of treatment. 
 
Key findings included: 
 Both buprenorphine and methadone demonstrated 
increases in heroin-free days; and  
 There was no statistical significance between the 
cost-effectiveness for buprenorphine and methadone. 
 
Reference: 
 
Doran, C. M., Shanahan, M., Mattick, R. P., Bell, J., White, J., & Ali, R. 
(2003). Buprenorphine versus methadone maintenance: A cost 
effectiveness analysis. Drug and Alcohol Dependence, 71(3): 29 –302. 
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Slide 27:  Use of Buprenorphine:  Studies on Cost-
Effectiveness, cont’d 
  
Another study conducted by Kaur and McQueen (2008) 
found that the treatment with buprenorphine/naloxone was 
associated with a reduction in opioid utilization and cost in 
the first year of follow-up. 
 
Doran (2008) conducted a systematic review of the 
literature and found a number of studies supporting 
buprenorphine as a cost-effective approach to opioid 
treatment. 
 
References: 
 
Doran, C. M. (2008). Economic evaluation of interventions to treat 
opiate dependence: a review of the evidence. Pharmocoeconomics, 
26(5), 371-393. 
 
Kaur, A. D., McQueen, A. & Jan, S. (2008). Opioid drug utilization and 
cost outcomes associated with the use of buprenorphine-naloxone in 
patients with a history of prescription opioid use. Journal of Managed 
Care Pharmacy, 14(2), 186-194. 
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Slide 28:  Use of Buprenorphine:  Studies on Cost-
Effectiveness, cont’d 
  
This study was the first to examine the cost effectiveness 
of buprenorphine as maintenance treatment for heroin 
dependence in a primary care setting. The study was a 
randomized, open-label, 12-month trial of 139 heroin-
dependent patients in a community setting receiving 
individualized treatment regimens of buprenorphine or 
methadone. The study took a broad societal perspective 
and included health, crime and personal costs. The main 
outcomes were incremental cost per additional day free of 
heroin use and per the quality adjusted life years (QALY). 
 
The researchers found that buprenorphine demonstrated 
lower crime costs and higher quality adjusted life years. 
 
Reference: 
 
Harris, A. H., Gospodarevskaya, E., & Ritter, A. J. (2005). A 
randomised trial of the cost effectiveness of buprenorphine as an 
alternative to methadone maintenance treatment for heroin dependence 
in a primary care setting. Pharmocoeconomics, 23(1), 77-91.  
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Slide 29:  What is the Ratio of Buprenorphine to 
Naloxone in the Combination Tablet  
  
The combination includes buprenorphine and naloxone in 
a ratio of 4:1.  
 
This ratio was found to maintain the clinical effects when 
taken sublingually as intended, BUT cause sufficient 
discomfort if injected by a physically dependent person (to 
discourage them from doing so).  
 
Slide 29 
 
Slide 30:  Why Combining Buprenorphine and 
Naloxone Sublingually Works  
  
Digestive juices would kill buprenorphine’s effects if you 
were to swallow it. By administering it sublingually, the 
medication dissolves under the tongue and is absorbed 
directly into the blood stream. Buprenorphine and 
naloxone have very different absorption rates when taken 
this way.  
 
When taken under the tongue, the person receives 
approximately 40-60% of the buprenorphine available, but 
only 10% of the naloxone.  
  
However, when you look at the relative potency comparing 
sublingual administration to injection, buprenorphine is 
approximately twice as strong when injected as when 
taken sublingually. Naloxone, on the other hand, is 15 
times more effective by injection.  
  
This means that when injected, the naloxone is the 
stronger medication and the antagonist effects dominate.  
 
Reference: 
 
Chiang, C.N., & Hawks, R.L. (2003). Pharmacokinetics of the 
combination tablet of buprenorphine and naloxone. Drug and Alcohol 
Dependence, 70, S39-S47. 
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Slide 31:  Buprenorphine/Naloxone:  What You Need 
to Know 
 
 The effect of the combination tablet is virtually 
identical to the buprenorphine-only product when 
taken sublingually. 
 Both formulations demonstrate the ceiling effect at 
higher doses. 
 Both formulations prevent the intoxicating effects if 
someone decides to also use another opioid. 
 They are long-acting because of the high receptor 
affinity, meaning they bind strongly to the receptor 
site. 
 
Additional Information for the Trainer(s): 
 
Safety  
 
Because of its ceiling effect and poor bioavailability, 
buprenorphine is safer in overdose than opioid full 
agonists. The maximal effects of buprenorphine appear 
to occur in the 16–32 mg dose range for sublingual 
tablets. Higher doses are unlikely to produce greater 
effects.  
 
Respiratory depression from buprenorphine (or 
buprenorphine/ naloxone) overdose is less likely than 
from other opioids. There is no evidence of organ 
damage with chronic use of buprenorphine, but 
increases in liver enzymes are sometimes seen. There is 
no evidence of significant disruption of cognitive or 
psychomotor performance with buprenorphine 
maintenance dosing.  
 
Side Effects  
 
Side effects of buprenorphine are similar to those of 
other opioids and include nausea, vomiting, and 
constipation. Buprenorphine and 
buprenorphine/naloxone can precipitate the opioid 
withdrawal syndrome. Additionally, the withdrawal 
syndrome can be precipitated in individuals maintained 
on buprenorphine. 
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Slide 32:  Clonidine  
  
Clonidine (Catapres®; most often used to treat 
hypertension) has gained widespread recognition and 
acceptance for its usefulness as an agent for symptom 
suppression of opioid withdrawal.  
  
Clonidine has some practical advantages for treating 
opioid withdrawal, including: 
 It is not a scheduled medication.  
 The use of opiates can be discontinued immediately in 
preparation for naltrexone induction or admission to a 
psychosocial treatment program.  
 No special license is needed. 
 It can be used in inpatient and outpatient settings; it is 
most effective when used in an inpatient setting as 
side effects can be monitored more closely. 
 It partially suppresses peripheral symptoms of opiate 
withdrawal (e.g., nausea, vomiting, sweating, 
diarrhea), however, it is not effective at alleviating 
subjective effects of opiate withdrawal (e.g., general 
body aches, abdominal cramps, cravings, etc.).  
 
Clonidine does not have an FDA indication for treatment 
of opioid dependence. However, once a medication has 
been approved for marketing for a certain use, experience 
may show that it is also useful for other medical problems. 
Other off-label uses of clonidine include the following 
medical conditions:   
 Migraine headache   
 Symptoms associated with menopause or menstrual 
discomfort   
 Symptoms of withdrawal associated with alcohol, 
nicotine, or narcotics   
 
Off-label use is usually based on anecdotal case reports 
and/or small, uncontrolled studies that indicate efficacy in 
a specific population. Generally, there are no clinical trials 
to support it.  
  
One of the difficulties in using a medication off-label, 
therefore, is that there is little or no information from 
clinical trials relating to proper dosage, precautions, or 
side effects for these off-label uses. The treating physician 
must use clinical experience to address these issues.  
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Slide 33:  Contraindications for Use of Clonidine  
  
Contraindications for use of clonidine include 
hypertension, hypotension, pregnancy, liver damage, 
history of auditory hallucinations, delirium, recent 
myocardial infarction, chronic renal failure, and history of 
fainting or dizziness on rising.  
 
Clonidine is in Category C for pregnancy. This means that 
there is not enough information to determine if it is safe for 
use in pregnant women. 
 
What are the safety issues of clonidine vs. buprenorphine–
especially in an outpatient setting (if the medication is not 
used as indicated)?   
 
If the medication is not used as indicated, clonidine will 
add to the effects of alcohol and other central nervous 
system (CNS) depressants (medicines that slow down the 
nervous system, possibly causing drowsiness). Examples 
of CNS depressants include antihistamines or medicine for 
hay fever, other allergies, or colds; sedatives, tranquilizers, 
or sleeping medicine; prescription pain medicine or 
narcotics; barbiturates; medicine for seizures; muscle 
relaxants; or anesthetics, including some dental 
anesthetics.  
 
It may also cause some people to become drowsy or less 
alert than they are normally.  
 
Dizziness, lightheadedness, or fainting may occur, 
especially when you get up from a lying or sitting position. 
This is more likely to occur if you drink alcohol, stand for 
long periods of time, exercise, or if the weather is hot.  
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Slide 34:  Medically-Assisted Withdrawal  
(a.k.a. Dose Tapering; a.k.a. Detoxification)  
  
The data from the study clearly indicates that 
buprenorphine was more effective than clonidine (a 
standard treatment) in this 13-day taper. Before we look at 
the specifics of how to implement this taper, let’s talk 
about opioid withdrawal and what patients experience 
when going through it.  
  
Opiate withdrawal syndrome, although not life-threatening, 
is a major obstacle in the treatment of opiate dependence. 
Detoxification from opiate dependence most often involves 
the administration of an opiate agonist (e.g., methadone) 
or the non-opiate clonidine (Fishbain, Rosomoff, & Cutler, 
1993; Valmana, 1999).  
  
Withdrawing from opioids is often the first step in the 
treatment of opioid dependence. It is the start of a 
continuum of care that needs to be carefully planned and 
followed.  
  
Not all patients are appropriate for withdrawal from opioids 
and may need to continue receiving their medication for an 
extended period. Unstable living situations, multiple 
relapses, previous failed detoxification attempts, or lack of 
desire to withdraw from opioids, may indicate that 
medication maintenance is a better treatment option.  
 
References: 
 
Fishbain, D. A., Rosomoff, H. L., & Cutler, R. (1993). Opiate 
detoxification protocols. A clinical manual. Annals of Clinical Psychiatry, 
5(1), 53–65.  
 
Valmana, A. (1999). Non-methadone pharmacotherapies in opioid 
addiction. Current Opinion in Psychiatry, 12(3), 307-310. 
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Slide 35:  Withdrawal  
  
Withdrawal syndrome:  the predictable constellation of 
signs and symptoms following abrupt discontinuation of, or 
rapid decrease in, intake of a substance that has been 
used consistently for a period of time.  
  
Detoxification:  implies a clearing of toxins (Alling, 1992). 
However, for individuals with physiological substance 
dependence, detoxification is defined as the management 
of the withdrawal syndrome (Center for Substance Abuse 
Treatment, 2006). In this training, we will refer to this as an 
opioid taper.  
 
References: 
 
Alling, F. A. (1992). Detoxification and treatment of acute sequelae. In 
J.H. Lowinson, P. Ruiz, R.B. Millman & J.G. Langrod (Eds.), Substance 
abuse: A comprehensive textbook (second edition), (pp. 402-415). 
Baltimore: Williams & Wilkins. 
 
Center for Substance Abuse Treatment. Detoxification and Substance 
Abuse Treatment. Treatment Improvement Protocol (TIP) Series 45. 
DHHS Publication No. (SMA) 06-4131. Rockville, MD: Substance 
Abuse and Mental Health Services Administration, 2006. 
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Slide 36:  Withdrawal Syndrome  
Once the body becomes accustomed to a drug being on 
board, it may react if the drug is removed. The intensity of 
the withdrawal symptoms will depend on the level of use 
(e.g., dose and type of opioid) and the frequency and 
duration of use (chronicity).  
Withdrawal symptoms are basically a rebound effect:  
those functions that have been depressed or altered by 
the opioid suddenly emerge again. Withdrawal symptoms 
are often the opposite of symptoms seen when actively 
using the opioid (e.g., people get constipated when taking 
opioids and have diarrhea when withdrawing).  
Length of withdrawal depends upon the half-life of the drug 
used. Opioids with short half-lives (e.g., heroin) have acute 
withdrawal symptoms that peak at days 3-4 and then 
subside by days 3-7. Opioids with longer half-lives have 
longer acute withdrawal periods.  
Regardless of the length of the acute withdrawal, there are 
protracted withdrawal symptoms (e.g., aches and pains, 
general malaise) that persist for weeks or months after use 
ceases. 
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Slide 37:  Medically- Assisted Withdrawal  
  
The individual is systematically withdrawn from addicting 
drugs. Medications (e.g., methadone, buprenorphine, and 
clonidine) are used to alleviate withdrawal symptoms while 
the person gradually returns to an opioid-free state. It can 
be done successfully in inpatient or outpatient settings. 
  
Generally, a medical provider supervises the withdrawal to 
monitor medical safety and administer medications to 
relieve discomfort.  
 
This approach is not sufficient by itself to transition 
someone to maintaining an ongoing opioid-free life. 
Longer-term treatment that helps the person to develop 
new behaviors and strategies for coping is critical.  
  
Patients who are not successful in withdrawing or who 
choose not to withdraw from opioids should be considered 
for treatment with medications as part of the treatment 
plan. 
 
Slide 37 
 Short Term Opioid Withdrawal Using Buprenorphine Training Manual   Page 37 
 
 
Slide 38:  Principles of Medically-Assisted Withdrawal  
 
Some withdrawal procedures are specific to particular 
drugs of dependence, while others are based on general 
principles of treatment and are not drug-specific.  
Because there is a risk of serious adverse consequences 
for some patients who undergo withdrawal, an initial 
assessment should be conducted that includes the amount 
and duration of a patient's use of alcohol and/or other 
drugs; the severity of the patient's prior withdrawal 
experiences, if any (many individuals undergo the 
withdrawal process more than once); and the medical and 
psychiatric history.  
Strategies for pharmacologic management of withdrawal:  
(1) suppression of withdrawal by transitioning the patient 
onto a long-acting opioid (e.g., buprenorphine or 
methadone) and then tapering the medication over a 
period of time);  
(2) decreasing signs and symptoms of withdrawal (i.e., 
use of ancillary medications to treat symptoms). 
Medication-assisted withdrawal alone rarely constitutes 
adequate treatment. Psychological support is essential in 
reducing the patient's distress during the withdrawal 
process.  
The appropriate level of care following withdrawal is 
clinically determined, based on the individual needs of the 
patient. Factors to consider include medical and 
psychiatric conditions, motivation, relapse potential, and 
available support system. 
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Slide 39:  Why the Focus on Medically-Assisted 
Withdrawal (Detoxification)?  
 
Bullet #1:  Much of the data that has been generated on 
the use of buprenorphine has focused on its use as a 
maintenance agent. Less is known about how to use it for 
opioid withdrawal.  
 
Bullet #2:  More research is critical if we are to understand 
the best ways of using the medication to assist with 
patients with withdrawal from opioids.  
 
Bullet #3:  Community Treatment Programs participating in 
the CTN span the diversity of treatment options available 
in the field. By studying treatment innovations in this 
environment, a good picture can be achieved of how the 
treatment will work in the community at large.  
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Slide 40:  The Research:  CTN Protocols 0001 and 
0002 (Transition Slide) 
  
This package of materials is based on research conducted 
through the CTN.  
  
For the first studies conducted by the CTN, NIDA chose to 
compare a standard treatment for helping patients taper 
from opioids (clonidine) to a new treatment 
(buprenorphine). Two clinical trials were developed and 
implemented to compare these medications. 
 
Reference: 
 
Ling, W., Amass, L., Shoptaw, S., Annon, J. J., Hillhouse, M., Babcock, 
D., et al. (2005). A multi-center randomized trial of buprenorphine-
naloxone versus clonidine for opioid detoxification: Findings from the 
National Institute on Drug Abuse Clinical Trials Network. Addiction, 100, 
1090-1100. 
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Slide 41:  The Two Buprenorphine-Naloxone Protocols 
 
The studies were identical, except for the type of treatment 
program in which the program was conducted. The first 
protocol was conducted in inpatient settings and the 
second was conducted in outpatient settings.  
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Slide 42:  Site Participation NIDA-CTN 0001  
  
Overall, the studies were conducted in eight Regional 
Nodes and 12 Community Treatment Programs  
  
For the inpatient protocol, six sites in five regional nodes 
across the country participated in the study. 
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Slide 43:  Site Participation NIDA-CTN 0002  
 
For the outpatient protocol, six sites in five nodes 
participated in the study.  
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Slide 44:  NIDA CTN 0001/0002 Buprenorphine 
Naloxone Detoxification Protocols  
 
As information is being gathered to determine whether or 
not a medication is effective for treatment of a particular 
problem, the studies are usually blinded. This means that 
the patients (and usually the researcher) do not know if a 
particular patient is taking the active medication or a 
placebo/other medication. It is only after the study is 
completed that the blind is broken and the researcher can 
evaluate the effect of the medications. These blinding 
procedures prevent expectations about the medication (or 
placebo) from positively or negatively influencing the 
results.  
 
After efficacy of the medication has been established, 
researchers may want to explore specific indications or 
ways of using the medication. These studies are often 
open-label studies—both patients and researchers know 
what they are taking—which was the case in these 
studies.  
 
Another way that researchers control bias or expectations 
from influencing the results is through randomization. This 
means that the person is assigned to their study group by 
chance. In the current study, participants were randomly 
assigned to receive either buprenorphine or clonidine. 
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Slide 45:  Community Treatment Programs  
  
There was considerable variability in several areas in both 
the inpatient and outpatient programs. CTP and 
physicians’ experience with opioid users and narcotic 
treatment medications varied. Nine of the 12 physicians 
participating were certified by the American Society for 
Addiction Medicine; all actively treated substance abusers; 
training backgrounds included addiction psychiatry, 
internal or family medicine, pediatrics or anesthesiology; 
and professional experience ranged from 1 to 20 years.  
  
The majority of the participating programs were based in 
urban settings, with only one located in a more rural 
setting. Nine of the 12 programs were public non-profit; 
one program was public for-profit; and one program was 
private for-profit. 
 
Experience participating in research also varied. Some 
had many years of experience participating in research 
while others never participated.  
  
In the inpatient programs, about half of the programs 
currently provided detoxification with methadone and half 
with clonidine. In outpatient, four of the six programs were 
methadone programs and used methadone, the other two 
used clonidine.  
 
This variability in the programs suggests that the results 
can be interpreted beyond a specific type of program, but 
the results are probably applicable to a variety of different 
program types.  
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Slide 46:  Study Schema  
  
The goal of CTN 0001 and 0002 was to compare the 
efficacy of these two medications for short-term opioid 
withdrawal. The 2-week timeframe was decided upon by 
the investigators. The time frame was long enough to 
cover the length of time for someone who quit “cold turkey” 
to be through the acute withdrawal period. This timeframe 
also met requirements of several agencies’ funding 
restrictions related to length of stay. Thus, this was a 
schedule that could be implemented in programs if the 
research proved its efficacy.  
  
A standard taper schedule was used so that all patients 
received buprenorphine or clonidine according to a 
predetermined schedule on each day of the taper. 
Ancillary medications were available to treat breakthrough 
withdrawal symptoms.  
  
This slide shows the order of procedures for participants in 
the study. After obtaining informed consent, baseline 
screening and assessments were conducted. Participants 
were then randomized in a 2:1 ratio to buprenorphine or 
clonidine. Participants received medication and evaluation 
for 13 days and then were followed up at 1, 3 and 6 
months. 
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Slide 47:  Primary Efficacy Endpoint  
  
The researchers conducting this study were testing the 
hypothesis that buprenorphine would be associated with 
better treatment response compared to clonidine To test 
this hypothesis, they needed to define a way to measure 
treatment response.  
  
A positive treatment response was defined as being 
present on the final day of the taper (day 13, the last day 
to receive medication OR day 14, the first day off of the 
medication), AND providing an opioid-free urine sample 
(meaning no illicit opioids had been used).  
  
Note to the Trainer(s):  It is important to note that this 
study addressed only the process of tapering patients off 
of opioids so that at the end of the taper they were opioid 
free. Ongoing care and follow-up were not addressed in 
the result of this trial, but are thought to be important 
considerations for patients who receive this taper in real-
world settings.  
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Slide 48:  So, what did we find?  
 
The results from this study were pretty dramatic. Let’s look 
at the inpatient study first. 
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Slide 49:  Demographics 0001 (Inpatient)  
 
Demographics were similar across the two groups. They 
were:  
 Predominantly male;  
 Predominantly white, but with representation from 
other ethnic minority groups.  
 Participants were in their mid-30s.  
 Two-thirds were employed.  
 They had been using heroin for about 6.5 years at the 
time they began the study.  
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Slide 50:  Present and Opioid Negative 0001 (Inpatient) 
  
Data collection visits were conducted according to this 
schedule (Day 3-4, 7-8, 10-11, and 13-14). Urine samples 
were collected at each visit. Collection was not directly 
observed, but monitored using temperature testing. The 
data presented in the slides at this point pertains 
specifically to opioid-free urines.  
  
Among the participants in the inpatient study, ¾ of 
participants were present at the end of the taper AND 
provided an opioid-negative urine sample. In the clonidine 
group, only 22% were present and opioid negative at the 
end of the taper.  
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Slide 51:  Present and Opioid Negative 0001 (Inpatient) 
  
This slide shows the same information graphically. At the 
end of the withdrawal, buprenorphine was 3.4 times more 
effective than clonidine in helping people to be present 
and opioid negative. 
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Slide 52:  Demographics 0002 (Outpatient)  
  
In the outpatient study, there was a higher percentage of 
male participants than in the inpatient study (72% vs. 
60%). The proportion of minority participants was higher in 
this study as well (60% vs. 44%). The participants were 
slightly older (39 vs. 36 years old) and had been using 
heroin longer than those in the inpatient study (9.4 vs. 6.6 
years). 
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Slide 53:  Present and Opioid Negative 0002 
(Outpatient)  
  
Overall, the numbers present and opioid negative at the 
end of the taper were lower than in the inpatient study. 
The researchers expected this difference given the fact 
that in the inpatient settings, clients were contained within 
the treatment environment. In outpatient settings, 
participants are still living in their environments and, 
therefore, come in contact with more factors that can pull 
them away from treatment. In spite of the lower numbers, 
however, the results are still dramatic.  
  
At the end of the taper, nearly one in three participants 
receiving buprenorphine were present and provided an 
opioid negative urine sample. In the clonidine group, only 
one in 20 participants were present and opioid free.  
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Slide 54:  Present and Opioid Negative 0002 
(Outpatient)  
  
Again, this slide shows the same information graphically. 
At the end of the withdrawal, buprenorphine was 5.4 times 
more effective than clonidine in helping people to be 
present and opioid negative. 
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Slide 55:  NNT:  Number Needed to Treat  
  
Another way of looking at these data is to look at the 
number of patients that need to be treated in order to get 
one successful outcome (again defined as a positive 
treatment response—present and opioid negative).  
  
If you take the total number of participants receiving a 
treatment and divide by the number successfully 
completing the treatment, you get the number of patients 
you need to treat (on average) for one successful 
treatment.  
  
Using this methodology, in the inpatient study you need to 
treat 1.3 patients with buprenorphine to get one successful 
outcome versus 4.5 when treatment with clonidine. Stated 
another way, you would need to treat 3.4 times more 
people with clonidine than with buprenorphine to get a 
positive treatment response.  
  
In the outpatient, study you need to treat more people to 
get a positive result. With buprenorphine, you need to treat 
3.4 patients to get one successful outcome. However, with 
clonidine you need to treat 18.5 patients, which means 
that you would need to treat 5.4 times more people with 
clonidine than with buprenorphine to get a positive 
treatment response.  
  
Ask participants, “What are the implications of this for 
deciding how to treat patients?”  
  
Possible answers/discussion points:  Treating with 
buprenorphine is more likely to lead to a successful 
taper; patient experience is better with buprenorphine; 
if an individual patient is selecting a treatment, they 
would want to choose the one with the higher 
likelihood of success.  
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Slide 56:  Protocol  
  
This protocol was designed to examine the use of 
Suboxone® (buprenorphine/naloxone) versus the use of 
clonidine in a short-term opioid withdrawal, in inpatient and 
outpatient settings.  
  
The three main objectives of the program were:  
 Improved patient compliance and treatment retention.  
 Opioid abstinence should be achieved.  
 Minimal abstinence symptomology should result from 
the dose reduction schedule in order to minimize the 
risk for relapse.  
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Slide 57:  The results of the protocol were pretty 
dramatic  
 
In summary, the result of this protocol supports the use of 
buprenorphine for this 13-day taper schedule.  
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Slide 58:  Outcomes  
  
A 13-day taper, utilizing a prescribed schedule, 
demonstrated the following results:  
 The taper using buprenorphine was successful in both 
outpatient and inpatient settings  
 Buprenorphine was superior to clonidine in both 
settings  
 The percent of those present and opiate clean at day 
13 was higher among the inpatient buprenorphine 
patients (76%) than among the inpatient clonidine 
patients (22%).  
 The percent of those present and opiate clean at day 
13 was higher among the outpatient buprenorphine 
patients (29%) than among the outpatient clonidine 
patients (5%).  
 Generalizability is supported by:  representative 
sampling of minority populations and the sample 
population was geographically representative.  
 The sample population given Suboxone® had lower 
withdrawal symptoms. 
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Slide 59:  So if I want to do this, what steps do I take? 
(Transition slide) 
  
Read text 
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Slide 60:  First, the patient must be screened for 
appropriateness for buprenorphine treatment  
  
Most patients can be considered for treatment with 
buprenorphine provided they are opioid dependent and 
interested in medication-assisted withdrawal. 
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Slide 61:  Screening Assessment Used in the CTN 
Protocols  
  
Prior to participation in the protocol, a screening 
assessment was completed and included:  
 Medical history and history of prior medication use;   
 Psychiatric evaluation (Addiction Severity Inventory 
Lite);  
 DSM-IV checklist for substance dependence;  
 HIV risk assessment; and 
 Hepatitis B and C Serology.  
 
It is important to note that the effect of hepatic impairment 
on buprenorphine and naloxone is unknown. Since both 
drugs are extensively metabolized, the plasma levels will 
be expected to be higher in patients with moderate and 
severe hepatic impairment. In patients with hepatic 
impairment, dosage should be adjusted and patients 
should be observed for symptoms of precipitated opioid 
withdrawal.  
  
An HIV risk assessment was included for two main 
reasons: this particular assessment is used in all CTN 
studies; and individuals who are injecting drugs are at a 
higher risk for HIV infection and Hepatitis C, which may 
complicate addiction treatment. 
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Slide 62:  Safety Assessment Used in the CTN 
Protocols  
A safety assessment was conducted with each patient and 
included:  
 Physical examination   Urinalysis  
 Vital signs   12 Lead  
 Blood chemistry electrocardiograph (ECG) 
 Hematology  Pregnancy test 
 
Numerous studies have demonstrated that, when taken as 
recommended, buprenorphine has been well tolerated and 
that there are few significant side effects.  
The question has been asked, “Do you really need to do a 
physical to give someone buprenorphine?” In the CTN 
studies a physical exam was conducted as part of the 
safety assessment for participation in the study. The 
protocol was overly stringent with regard to exclusion 
criteria because a patient could be randomized to receive 
clonidine, which, as previously discussed, has several 
contraindications.  
It may be good to have the baseline assessment to 
determine their general health and identify other issues that 
may need treatment (hooks them into the medical system, 
even if it is not completely necessary to start someone on 
buprenorphine). As with all medical decisions, the physician 
should use his/her best medical judgment to determine if 
and when this should occur.  
Additional Note for the Trainer(s):  At the time of the 
development of this module, there are no adequate and 
well-controlled studies of Suboxone® in pregnant women. 
However clinical studies are currently underway and 
showing promising results. Of special note: use of high 
doses of sublingual buprenorphine in pregnant women has 
shown that buprenorphine passes into the mother’s milk. 
Breast-feeding is therefore not advised in mothers treated 
with Suboxone®.  
Additional Information for the Trainer(s):  Jones, et al. 
(2005) conducted a study of pregnant women who enrolled 
during their second trimester. The only statistically 
significant finding is that women receiving buprenorphine 
required shorter hospital stays than women on methadone. 
Trends indicated that fewer infants needed to be treated for 
Neonatal Abstinence Syndrome (NAS) and that less NAS 
medications were needed when treated with buprenorphine 
compared with methadone. A multi-site replication trial is 
now underway. 
Reference: 
Jones, H. E., Johnson, R. E., Jasinski, D. R., O’Grady, K. E., Chisholm, 
C. A., Choo, R. E., et al. (2005). Buprenorphine versus methadone in the 
treatment of pregnant opioid-dependent patients: Effects on the neonatal 
abstinence syndrome. Drug and Alcohol Dependence, 79, 1-10. 
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Slide 63:  Once you determine that buprenorphine is 
the best treatment…the next step is induction  
  
Starting the patient on the medication is pretty 
straightforward, but must be planned in order to ensure a 
smooth transition onto buprenorphine. If buprenorphine is 
not given appropriately, an opioid dependent patient can 
experience withdrawal symptoms.  
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Slide 64:  Transferring Patients Onto Buprenorphine:  
3 Ways Significant Withdrawal Could Occur  
  
There are three ways that a patient can experience 
withdrawal symptoms.  
  
First, if an insufficient dose of buprenorphine is given, the 
person may experience withdrawal from being under 
medicated. 
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Slide 65:  If dose is too low, the patient will experience 
withdrawal  
  
This graph represents how under-medication can result in 
withdrawal symptoms. If the patient is given a low level of 
medication (represented by the green line), but needs 
higher level in order to not feel sick (represented by the 
white line), the person will feel sick unless the dosage is 
increased to bring them up to this level. 
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Slide 66:  Transferring Patients Onto Buprenorphine:  
3 Ways Significant Withdrawal Could Occur  
  
A second way that a person can experience withdrawal 
has to do with the properties of buprenorphine itself—the 
ceiling effect.  
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Slide 67:  If the patient needs a high level of 
medication to achieve maintenance, the ceiling effect 
of buprenorphine may result in withdrawal  
  
As described before, as the dose of buprenorphine 
increases, the agonist effects level off. For someone who 
is dependent on very high doses of opioids, they may 
need an effect greater than can be achieved with 
buprenorphine in order to not feel sick.  
  
In this case, treatment would need to be provided using a 
full agonist (e.g. methadone), or the person would need to 
taper down their level of drug use before switching to 
buprenorphine. This can be done in a structured opioid 
treatment program, and should not be attempted with 
someone using illicit opioids.  
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Slide 68:  Transferring Patients Onto Buprenorphine:  
3 Ways Significant Withdrawal Could Occur  
  
Finally, there is precipitated withdrawal. This also has to 
do with the ceiling effect and receptor affinity.  
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Slide 69:  Buprenorphine will replace other opioids at 
the receptor site; therefore, the patient experiences 
withdrawal.  
  
If the person is currently intoxicated on an opioid, the 
opioid receptors are filled with this drug. Buprenorphine, 
however, has a stronger affinity for the receptors than illicit 
opioids and will replace these opioids on the receptor. Due 
to the ceiling effect, it’s as if the level of opioids in the 
system has suddenly decreased, and the patient will 
experience this as withdrawal.  
  
In order to avoid this, buprenorphine should only be 
administered once the person is in mild withdrawal. This 
will result in a reduction of the withdrawal symptoms and 
the experience of feeling better/normal. 
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Slide 70:  Buprenorphine is administered sublingually. 
  
The sublingual tablet should be held under the tongue until 
dissolved, which can take 2 to 10 minutes.  
  
For this protocol, dissolution was monitored by personnel 
at the clinic by looking under the tongue to ensure that the 
tablet was gone to ensure that all of the medication had 
been taken.  
 
Slide 70 
 
Slide 71:  What will the tablets look like? How will they 
taste?  
  
The Suboxone tablets were the ones chosen for these 
protocols since the pharmacology of the 
buprenorphine/naloxone combination is the same as for 
buprenorphine alone, and the combination reduces the 
chance of diversion as described previously.  
  
The tablets are orange and have a citrus flavor to mask 
the bitter taste experienced by some people.  
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Slide 72:  Five Steps to Starting Bup/Nx  
  
There are five recommended steps for initiating treatment 
with buprenorphine.  
  
First, it is recommended that the patient be in mild 
withdrawal prior to taking their first dose of buprenorphine. 
This means that they must abstain from use of illicit 
opioids prior to induction. For short acting opioids (e.g., 
heroin), an interval of about 8 hours is recommended. For 
longer acting opioids, the interval will need to be increased 
to 24 or even 48 hours.  
  
Mild withdrawal can be evaluated based on clinical signs. 
Using a structured instrument such as the Clinical Opioid 
Withdrawal Scale (COWS), developed by Wesson and 
Ling (2003), can provide a way of rating these clinical 
signs to determine opioid withdrawal.  
  
Clinical Opiate Withdrawal Scale (COWS). This is an 11-
item interviewer administered questionnaire designed to 
provide a description of signs and symptoms of opiate 
withdrawal that can be observed directly in the patient 
(e.g., sweating, runny nose, etc.)—provides for accurate 
objectification of symptoms, allowing for appropriate 
prescribing of medication.  
 
Reference: 
Wesson, D. R., & Ling, W. (2003). The Clinical Opiate Withdrawal Scale 
(COWS). Journal of Psychoactive Drugs, 35, 253-259. 
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Slide 73:  The Dosing Schedule  
  
The dosing schedule for this taper was uniform for 
everyone. This was necessary for research purposes. 
Additionally, the dosing schedule has the benefit of 
ensuring that people are brought onto buprenorphine as 
quickly as possible, and then tapered off over as long as 
possible.  
  
The specific dosing schedule is as follows: 
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Slide 74:  Day 1 Dose Induction  
  
During the research study, participants were asked to 
come to the clinic daily for medication, assessments and 
monitoring of withdrawal symptoms to determine the need 
for ancillary medications.  
  
The initial dose was always given to the patient in the 
clinic. They were assessed to be in mild withdrawal using 
the COWS and then were given 4 mg of buprenorphine 
sublingually. They were observed and a nurse checked 
under their tongue to make sure the medication had 
completely dissolved.  
  
Patients were instructed to wait in the clinic for two hours 
to ensure that they were tolerating the medication and to 
determine if an additional 4 mg of buprenorphine was 
indicated. The majority of patients received both 4 mg 
doses.  
  
On the second day of the study, the dose was 8 mg. This 
dose was given in a single administration rather than split 
as in day 1. On the third day, the dose increased to 16 mg. 
After day 3, the tapering of the medication began with 
decreasing dosages.  
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Slide 75:  BUP-NX Taper Schedule  
  
This list indicates the dosages for each day of the taper. 
Using this schedule, day 14 would be the first day that the 
patient is opioid free.  
  
Standard dosing was used throughout the protocol (the 
doses on the schedule were the doses administered).  
  
Patients were retained in the trial better in the 
buprenorphine group than in the clonidine group. In both 
groups, the majority of patients dropped out between day 
3 and 4. This is not surprising given that this is when the 
withdrawal symptoms would be most severe.  
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Slide 76:  The study was successful, but will it work 
for everyone?  
  
Any time you are evaluating research, it is important to 
look at the results carefully to determine how far the 
results can be generalized. The reality is, we can never 
really answer this question definitively, but we can 
generate some understanding of who this might work for 
by looking at who was included in the study and who was 
excluded. 
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Slide 77:  Inclusion Criteria for the CTN Protocols  
 
The inclusion and exclusion criteria for participation in this 
trial were very stringent. This is due in part to the fact that 
the comparison group received clonidine, which, as we 
have already discussed, has significant contraindications. 
We cannot determine from this study how the results may 
change if these criteria were less stringent.  
 Both buprenorphine and clonidine are labeled as 
Category C for pregnancy.  
 
This means that EITHER animal studies have revealed 
adverse effects on the fetus and there are no 
controlled studies in women OR studies in women and 
animals are not available. Drugs should be given only 
if the potential benefit justifies the potential risk to the 
fetus.  
 
Additionally, buprenorphine is labeled as “possible 
unsafe” during lactation and clonidine is labeled as 
“safety unknown.” For these reasons, pregnant and 
lactating women were excluded from the trial.  
 
 In order to be appropriate for a medically-assisted 
opioid taper, the person must be dependent on opioids 
and need assistance in getting off of them.  
 
 The blood pressure requirements were included 
primarily as a safety concern for patients receiving 
clonidine.  
 
The person must be in good enough health to participate 
safely in the trial and, in instances where they are 
receiving treatment, be willing to coordinate their care to 
ensure that their wellbeing is not compromised. 
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Slide 78:  Inclusion Criteria for the CTN Protocols, 
cont’d 
 
All participants in a research trial must be able to provide a 
valid informed consent. This means that the participant 
has had the nature of the study explained to them, 
including the details about the study, such as its purpose, 
duration, required procedures, key contacts, risks and 
potential benefits. The participant then decides whether or 
not to participate in the study. Minors cannot legally sign 
consent, so a parent or legal guardian would need to 
consent for them.  
Due to the concerns about pregnancy with these 
medications, use of an acceptable form of birth control 
was required from female participants. 
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Slide 79:  Exclusion Criteria for the CTN Protocols  
 
Clients were excluded from participation in the trial if they 
met any of these exclusion criteria:  
 If the person was found to have a significant medical 
conditions thought to potentially compromise the safety 
of the participant. Clinically, a physician may still 
decide to treat such patients with either of the 
medications being investigated in this trial, but it is 
unclear from these results what impact that will have 
on outcome.  
 If ECG anomalies were seen, a physician was asked 
to evaluate to determine if the finding was clinically 
significant.  
 Known allergy or sensitivity to any of the study 
medications would indicate that it is not an appropriate 
option for treatment. In the case of a research study, 
where the physician and the patient get no choice as 
to which medication the patient receives due to 
random assignment, sensitivity to any of the 
medications being studied would therefore exclude 
participation.  
 There are many medications known to negatively 
interact with clonidine. If the person was receiving any 
one of these, they were excluded from participation, 
again because random assignment may place them in 
the clonidine group, which would compromise their 
safety.  
Severe psychiatric issues or suicidal risk would exclude 
the person as they need to be stabilized urgently and then 
treatment of other conditions considered. 
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Slide 80:  Exclusion Criteria for the CTN Protocols , 
cont’d 
  
 Caution is advised for use of CNS depressants, 
especially benzodiazepines, due to increase risk of 
respiratory depression when combined with either 
buprenorphine or clonidine. Evaluation of level of use 
of these substances and/or need for medical 
detoxification is important in evaluating the safety for 
use with buprenorphine or clonidine.  
 Due to potential confounding of results, recent 
participation in another investigational trial excluded 
participation in this trial.  
 Regular use of long-acting opioids could potentially 
confound the results of this trial. Therefore, 
participants were excluded if they had been using 
them in the past month for maintenance or withdrawal 
from opioids. Additionally, participants were required to 
provide a methadone negative urine sample prior to 
induction with the study medications.  
 Pregnancy and lactating concerns have already been 
discussed above.  
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Slide 81:  Ancillary Medications for Treatment of 
Withdrawal Symptoms (Transition Slide) 
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Slide 82:  Ancillary Medications  
  
The use of ancillary medication during opioid withdrawal is 
fairly common, especially when using non-narcotic agents 
such as clonidine.  
  
Dispensing of ancillary medications was at the physician’s 
discretion, in accordance with clinical need, to assist with 
the management of withdrawal signs and symptoms. 
However, the choice of which medication could be given 
was limited.  
  
Most patients received at least one ancillary medication 
during the study.  
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Slide 83:  List of Ancillary Medications  
  
Following is a list of the ancillary medications that were 
used for this protocol.  
  
These medications were selected by consensus of the 
physicians participating in the trial. Medications were 
chosen based on their efficacy in treatment, a specific 
withdrawal symptom, and to provide the physicians with 
choices as to how to treat the symptoms. Once selected 
for the protocol, these medications were standardized and 
were the ONLY choices available for use.  
  
It is not clear what effect it will have on the course of 
treatment or the outcomes if different medications are 
used.  
  
Physicians were not required to dispense each ancillary 
medication, but rather to provide them according to their 
personal preference, practice, and patient’s clinical need. 
However, only one type of ancillary medication was 
administered for any given symptom on a given day. A 
physician could choose to try different medications across 
days.  
  
For outpatient programs, participants received the 
medication in a childproof bottle for self-administration at 
home in accordance with the printed instructions on the 
bottle.  
  
At the start of the medically-assisted withdrawal, patients 
were given instructions regarding the use of the 
medication. Refills were made available to all participants 
during each scheduled clinic visit. 
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Slide 84:  Ancillary Medications Used in CTN 
Protocols  
  
Following are the withdrawal symptoms and the 
medications that were available to treat them:   
  
Bone pain and Arthralgias  
 Acetaminophen (650 mg q 4-6 hrs;  
    NTE 3900 mg per 24 hrs)  
 Ibuprofen (800 mg q 8 hrs with food)  
 Methocarbamol (Robaxin) (500-1000 mg q 6 hrs prn; 
NTE 2000 mg per 24 hrs)  
 
Diarrhea  
 Loperamide (Immodium) (2 mg; NTE 8 mg per 24 
hrs)  
 Donnatal (1-2 tablets q 6-8 hrs prn;  
      NTE 8 tablets per 24 hrs) 
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Slide 85:  Ancillary Medications Used in CTN 
Protocols  
  
Anxiety and Restlessness  
 Lorazepam (1-2 mg q 6 hrs prn;  
    NTE 8 mg per 24 hrs)  
 Oxazepam (15-30 mg po q 6 hrs prn; 
    NTE 120 mg per 24 hrs)  
 Phenobarbital (15-30 mg po q 6 hrs prn; 
    NTE 120 mg per 24hrs)  
 Hydroxyzine hydrochloride (50 mg, po q 6 hrs prn; 
    NTE 200 mg per 24 hrs)  
 
Physicians prescribing the medications were aware of the 
cautions related to over use of benzodiazepines; dosages 
were selected to be effective for treating anxiety without 
putting the person at risk. Patients were also evaluated on 
an ongoing basis for misuse of the medication. 
Additionally, non-benzodiazepine options were available. 
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Slide 86:  Ancillary Medications Used in CTN 
Protocols  
  
Nausea  
 Trimethobenzamide (Tigan) (250 mg q 8 hrs prn;  
    NTE 750 mg per 24 hrs)  
 
Insomnia  
 Diphenhydramine (Benadryl) (25-50 mg;  
    NTE 300 mg per 24 hrs) 
 Zolpidem Tartrate (Ambien) (10 mg, 1-3 tabs, po q 
hs prn)  
 Trazadone Hydrochloride (50 mg, 1-3 tabs, po q hs 
prn)  
 Doxepin Hydrochloride (50 mg, 1-3 tabs, po q hs 
prn)  
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Slide 87:  Ancillary Medications Used Among Patients 
Receiving Buprenorphine  
  
There were no differences between groups in the rates of 
using ancillary medications in either the inpatient or the 
outpatient studies.  
 
Results indicated that about one in five participants (20%) 
received no ancillary medications. The other 80% received 
at least one medication.  
  
The most common symptoms treated were insomnia 
(most commonly treated with zolpidem tartrate [Ambien] or 
trazadone), bone pain and arthralgia (most commonly 
treated with ibuprofen), anxiety and restlessness (most 
commonly treated with lorazepam [Ativan] or oxazepam 
[Serax]). Only trimethobenzamide (Tigan) was available to 
treat nausea, and diarrhea was treated solely using 
loperamide (Immodium).  
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Slide 88:  Ancillary Medication Use  
  
Looking only at the participants receiving buprenorphine, 
you can see the steady decrease in patients receiving 
ancillary medications across the course of the study for all 
types of withdrawal symptoms. 
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Slide 89:  Adverse Events  
  
Patients reported additional symptoms or problems during 
the taper. These are defined in research protocols as 
adverse events. 
 
Slide 89 
 
Slide 90:  Adverse Events  
  
Information about adverse events is collected in all 
medically-related research studies.  
  
Adverse events are defined as any untoward medical or 
psychiatric occurrence during the patient’s participation in 
the trial.  
  
Adverse events may or may not be related to the 
treatment being provided.  
  
By collecting adverse event information, data concerning 
side effects of the treatment is obtained.  
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Slide 91:  Adverse Events  
  
A staff nurse or physician/clinician assessed adverse 
events on a daily basis during the withdrawal process and 
at the 1-month follow-up visit. The patient was asked, 
“How have you been feeling since I saw you last.” The 
type and severity of the adverse effect was recorded.  
  
Assessment instruments used included:  
 • Clinical Opiate Withdrawal Scale (COWS)  
   (For additional information, refer to Slide #72)  
 • Adjective Rating Scale for Withdrawal (ARSW)  
 • Visual Analog Scale (VAS)  
 
Adjective Rating Scale for Withdrawal (ARSW). The 
ARSW is comprised of 16 signs and symptoms of opioid 
withdrawal (Bickel, Stitzer, Bigelow, et al., 1988; Bickel, 
Stitzer, Liebson & Bigelow, 1988; Amass et al., 2000). 
Patients rate themselves on a scale ranging from 0 (none) 
to 9 (severe) (maximum cumulative score = 144) on the 
following items: muscle cramps, depressed or sad, painful 
joints, excessive yawning, hot or cold flashes, trouble 
getting to sleep, sick to stomach, irritable, runny nose, 
poor appetite, weak knees, excessive sneezing, tense and 
jittery, watery eyes, abdominal cramps, and fitful sleep.  
  
Visual Analog Scale (VAS). This scale consists of a 100-
point line anchored with “not at all” on one end (0) and 
“extremely” on the other (100).  
 
References: 
Bickel, W. K., Stitzer, M. L., Bigelow, G. E., Liebson, I.A., Jasinski, D. 
E., & Johnson. R. E.  (1988).  Buprenorphine: dose-related blockade of 
opioid challenge effects in opioid dependent humans.  Journal of 
Pharmacology and Experimental Therapeutics, 247, 47-53. 
 
Bickel, W. K., Stitzer, M. L., Liebson, I A., & Bigelow, G. E. (1988). 
Acute physical dependence in man: effects of naloxone after brief 
morphine exposure. Journal of Pharmacology and Experimental 
Therapeutics, 244, 126-132. 
 
Amass, L., Kamien, J. B., & Idulich, S.K. (2000). Efficacy of daily and 
alternate-day dosing regimens with the combination buprenorphine–
naloxone tablet. Drug and Alcohol Dependence, 58, 143-153. 
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Slide 92:  Adverse Events  
  
Differences were seen across groups in the number of 
adverse events reported per individual.  
In the inpatient study, significant differences were seen in 
the number of events reported for the total sample but not 
for those completing the taper. In the outpatient study, 
differences were seen in both the total sample and 
completers.  
It is impossible to compare the relative number of adverse 
events reported in the inpatient versus outpatient groups. 
It is likely that larger numbers were seen in the inpatient 
settings simply by virtue of the fact that they were in the 
facility 24-hours, allowing for increased observation, unlike 
in the outpatient settings where participants were only in 
clinic for study-related procedures. 
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Slide 93:  BUP/NX Safety Profile was Excellent  
  
Eighteen side effects were reported over the course of the 
clinical trial, including follow-up; 18 resulted in 
hospitalization and two resulted in death.  
 Sixty-one percent were associated with hospitalization 
for drug relapse or similarly related treatment.  
 Eighty-three percent transpired during the follow-up 
period.  
 The death that transpired was unexpected and 
discovered at the six month evaluation. It was 
associated with respiratory failure from a massive 
heart attack. The heart attack occurred four months 
following the completion of the taper and was not 
buprenorphine-naloxone related.  
 Only one event—hematemesis (vomiting blood), 
presumably due to bleeding from an esophageal 
tear—may have been study-related; it is possible the 
hematemesis was related to excessive hiccupping, 
which irritated the patient’s gastroesophageal mucosa 
and may have possibly been related to buprenorphine-
naloxone.  
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Slide 94:  The Role of Psychosocial Treatment During 
Medically-Assisted Opioid Withdrawal  
  
The purpose of this study was to evaluate the efficacy of 
buprenorphine versus clonidine for conducting this 13-day 
taper. It was implemented in a variety of settings and 
participants received psychosocial treatment as provided 
by the treatment agency. 
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Slide 95:  The Role of Psychosocial Treatment   
  
It was recognized by the investigators that participation in 
psychosocial counseling was very important. Previous 
research has also shown that participation in therapy helps 
to maximize the therapeutic effects of the medication.  
  
Note to the Trainer(s):  All participants were provided 
with a workbook entitled Opioid Dependence:  
Handbook for Recovery Using Buprenorphine by Dr. 
Walter Ling. This ensured that participants received the 
same basic level of information. However, no instruction 
was given about how to use this book or about other 
psychosocial treatment. Agencies provided psychosocial 
care as usual in their environment.  
  
The study’s weakness is also its strength. We gave some 
guidance as to how to provide the psychosocial treatment, 
but the study was not set up to examine what type of 
psychosocial treatment was provided and data were not 
collected about this.  
  
What the results indicate is that regardless of the type of 
psychosocial counseling provided, people receiving 
buprenorphine were more likely to be present and opioid 
free at the end of the taper than were those receiving 
clonidine.  
  
This speaks well for the treatment across settings. 
However, additional research is needed to determine what 
type of psychosocial treatment and/or what treatment 
elements are most effective in maximizing the results and 
helping the person to remain abstinent after the end of the 
taper.  
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Slide 96:  Key Lessons Learned from the CTN 
Experience (Transition Slide) 
  
In summary, let’s look at the lessons that were learned 
from Implementing this taper schedule in diverse inpatient 
and outpatient settings across the country.  
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Slide 97:  Lessons Learned  
  
(1) First, the medication was acceptable to the people 
taking it. Ninety percent (90%) of the participants in the 
buprenorphine group were successfully inducted onto the 
medication. That is, they received the first three doses and 
reached 16 mg.  
  
(2) Additionally, 3/4 of the participants completed the taper 
and were free from opioids on day 13. This indicates that 
this taper schedule is an effective way of engaging people 
in the treatment system.  
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Slide 98:  Lessons Learned  
  
(3) While the majority of participants experienced some 
negative symptoms that required use of an ancillary 
medication, generally, these were symptoms that are 
commonly seen during opioid withdrawal and not a 
negative effect of the medication.  
  
(4) There were few serious adverse events in the trial and 
only one may have been related to the medication. This 
indicates that buprenorphine is safe for use in these 
treatment settings.  
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Slide 99:  Lessons Learned  
 
There is considerable interest in buprenorphine among 
people seeking treatment for opioid dependence. Many of 
the programs had wait lists of people interested in entering 
the trial. Again, this demonstrates the acceptance of the 
medication among the target group for treatment.  
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Slide 100:  Lessons from Additional Analyses:  
Predictors of Treatment Success 
  
Ziedonis and his colleagues (2009) did additional analysis 
of data from this study to determine predictors of treatment 
success (i.e., being present and opioid free at the end of 
the taper). 
 
Predictors include: 
 Type of medication (buprenorphine) 
 Treatment setting (inpatient) 
 Degree of reduction in withdrawal symptoms in first 3 
days of treatment (greater reduction) 
 
Additionally, those in the clonidine group with better 
outcomes had lower withdrawal symptoms at baseline. 
 
Reference: 
 
Ziedonis, D. M., Amass, L., Steinberg, M., Woody, G., Krejci, J., Annon, 
J. J., et al. (2009). Predictors of outcome for short-term medically 
supervised opioid withdrawal during a randomized, multicenter trial of 
buprenorphine-naloxone and clonidine in the NIDA clinical trials 
network drug and alcohol dependence. Drug and Alcohol Dependence, 
99, 28-36. 
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Slide 101:  Lessons from a Study of Longer and 
Shorter Taper Schedules 
 
Ling and his colleagues (2009) conducted a follow-up trial 
in which all participants were stabilized for 4 weeks and 
then randomized to a 7- or 28- day taper. 
 
Results of this study showed no difference in treatment 
success between the groups. The authors concluded that: 
 A relatively quick taper may be advantageous and did 
not result in relapse to drug use at greater rates than a 
longer taper. 
 Patients stabilized physiologically on a range of 
buprenorphine doses can be tapered successfully 
over 7 days. 
 For patients who are stabilized, there was no 
advantage to prolonging the tapering schedule for 
weeks. 
 
Reference: 
 
Ling, W., Hillhouse, M., Domier, C., Doraimani, G., Hunter, J., Thomas, 
C., et al. (2009). Buprenorphine tapering schedule and illicit opioid use. 
Addiction, 104, 256-265. 
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Slide 102:  Additional Research 
 
Additional research is needed to determine: 
• To what degree do these patients return to opioid use 
following taper? 
• What counseling is best coupled with this taper? 
• What difference would it make if the treatment were 
provided in a physician’s office rather than in a 
substance abuse treatment program or clinic where 
other ancillary services are available? 
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Slide 103:  Questions? 
 
Ask if anyone has any questions. 
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